wi38 cell line  (ATCC)

Journal: Scientific Reports

Article Title: Targeting cancer expressed EGFR with a humanized monoclonal antibody

doi: 10.1038/s41598-026-46245-y

Figure Lengend Snippet: Binding of the humanized antibodies to EGFR. ( a ) Binding of the humanized antibodies at a 2 µg/ml to MDA-MB-468 cells. The bar represented by A1 was the chimera. Data represents the average of three different experiments. p values comparing A8, A10 and B8 to the chimera are < 0.001. ( b ) The best EGFR binders were tested on cells stable expressing EGFRvIII (F98npEGFRvIII), wild type EGFR (WI38) and amplified EGFR (MDA-MB-468) at 0.5 and 2 µg/ml. Cetuximab was used at a concentration of 2 µg/ml. The control is represented by the unstained cells. The figure is representative of three experiments.

Article Snippet: BT20, FaDu and WI38 were cultured in EMEM (ATCC, VA, USA).

Techniques: Binding Assay, Expressing, Amplification, Concentration Assay, Control

Journal: Scientific Reports

Article Title: Targeting cancer expressed EGFR with a humanized monoclonal antibody

doi: 10.1038/s41598-026-46245-y

Figure Lengend Snippet: A10 binding to EGFR. The binding affinity of A10 or 40H3 was determined on amplified ( a ), wild type overexpressed ( b ) and mutated EGFR-expressing tumor cells ( c ) by flow cytometry analysis. Cetuximab was used as positive control for wild type EGFR expressed on the normal fibroblast cell line, WI38. The antibodies were tested in a dose dependent manner as indicated (0.1–90 µg/ml). ( d ) The number of binding sites per cell was determined using each PE-labeled antibody at a concentration of 10 µg/ml.

Article Snippet: BT20, FaDu and WI38 were cultured in EMEM (ATCC, VA, USA).

Techniques: Binding Assay, Amplification, Expressing, Flow Cytometry, Positive Control, Labeling, Concentration Assay